Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arcutis Biotherapeutics, Inc.

< Previous 1 2 Next >
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis to Report Third Quarter 2023 Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Pricing of $100 Million Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Proposed Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis to Present at Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Appoints Interim Chief Financial Officer (CFO)
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis to Report Second Quarter Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis to Present at Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.